Fenugreek (Trigonella foenum-graecum L.) has properties which are hypolipidemic, hypocholesterolemic, hypoglycemic, insulinotropic, and antioxidant. These properties are related to the control of the Metabolic Syndrome, a disorder of carbohydrate and lipid metabolism which increases the risk of diabetes and cardiovascular disease. The purpose of this study was to evaluate the effect of fenugreek extract (Hydroxylean ® , Naturex) containing 25% of 4-hydroxyisoleucine (4-OH-Ile, isomer 2S,3R,4S) and 15.7% of trigonelline on peroxisome proliferator-activated receptor alpha (PPARα) transcriptional activity and Cu 2+ -induced low-density lipoprotein (LDL) oxidation in vitro. The activation of PPARα is linked to controlling lipidemia, cholesterolemia and glycemia, all associated with diabetes and cardiovascular disease. Also, the inhibition of LDL oxidation reduces the risk of stroke. 1,000 μg/mL of fenugreek extract showed a 31.2% activation of PPARα as compared with the positive control, 100 µM of fenofibrate. Fenugreek extract also inhibited LDL oxidation induced by Cu 2+ at concentrations higher than 5 μg/mL (P<0.01). To our knowledge, this is the first report on PPARα transcriptional activity and Cu 2+ -induced LDL oxidation in vitro for fenugreek extract rich in 4-OH-Ile and trigonelline. The findings support the current evidence on fenugreek's capacity to control the Metabolic Syndrome.
Fenugreek (Trigonella foenum-graecum L.) is used as a medicinal herb and spice. It lowers triglycerides and cholesterol [1] [2] [3] [4] [5] [6] [7] , reduces glycemia, improves insulin secretion, and is effective for the treatment of diabetes [6] [7] [8] . 4-Hydroxyisoleucine (4-OH-Ile), an amino acid found in fenugreek, is the principle active compound responsible for its insulinotropic effects [8] . Trigonelline, the principle alkaloid found in fenugreek, also shows hypoglycemic properties [9, 10] . Fenugreek improves the antioxidant status of the organism [11] [12] [13] [14] , but the evidence on its capacity to inhibit low-density lipoprotein (LDL) oxidation is still scarce.
The Metabolic Syndrome is a common disorder that is a result of the growing prevalence of obesity, which increases the risk of diabetes and cardiovascular disease [15] . This syndrome is characterized by abnormal lipid and carbohydrate metabolism with a low-grade inflammatory state. Peroxisome proliferator-activated receptors (PPARs) play an important role in these metabolic processes [16] . PPARs are ligand-activated transcriptional factors belonging to the nuclear receptor superfamily. Three different PPAR genes (α, β, also known as δ, and γ) have been identified. These genes display distinct patterns of tissue distribution and pharmacological profiles suggesting that each one [17] . PPARα is highly expressed in liver, heart, muscle, and kidney, where it has a crucial role in controlling fatty acid uptake and oxidation [18] . Ligands of PPARα are widely used to lower serum triglycerides and increase high-density lipoprotein (HDL) cholesterol in patients with obesity, dyslipidemia, atherosclerosis, and coronary heart disease [18] . Moreover, it is well accepted that LDL oxidation can contribute to the development and progression of atherosclerosis and therefore, should be lower in order to fight the onset of the Metabolic Syndrome. Indeed, highly cytotoxic oxidized LDL induces changes in endothelial cells and enhances proliferation of monocytes and smooth muscle cells, which increase the risk of stroke [19] .
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In order to investigate the potential of fenugreek for activating PPARα and inhibiting LDL oxidation, we tested a standardized fenugreek seed extract containing 25% of 4-OH-Ile and 15.7% of trigonelline (Hydroxylean In the HPLC of fenugreek extract, large peaks for trigonelline and 4-OH-Ile appear at 12 min and 19 min, respectively. These compounds were confirmed using HPLC-MS and NMR spectroscopic techniques. Trigonelline (N-methyl nicotinic acid) is the major alkaloid found in fenugreek. It has shown many functional properties, including inhibition of the invasion of hepatoma cells [20] , promotion of functional neurite outgrowth [21] , and glycemic control [9, 10] . Trigonelline is able to inhibit the sodium glucose cotransporter-1 (SGLT-1) mediated absorption of glucose across the brush border membrane [22] . The hypoglycemic effect of trigonelline has been observed using the compound alone [9] , or in combination with 4-OH-Ile [10] . The combination of trigonelline and 4-OH-Ile induces the formation of new pancreatic islets responsible for insulin secretion [10] . NMR confirmed that the 4-OH-Ile in our fenugreek extract is in the isomeric form (2S,3R,4S), which has more insulinotropic activity than the lesser found isomer (2R,3R,4S) in fenugreek seeds [8] .
The PPARα transcriptional activity assay showed that fenugreek extract is able to stimulate the PPARα nuclear receptor in a dose dependent manner ( Figure  1 ). Incubation of transfected COS-7 cells with fenugreek extract significantly activates PPARα at concentrations higher than 100 µg/mL (P<0.01) in comparison with the control condition (DMSO). At the highest concentration tested, 1,000 µg/mL, fenugreek extract gave a 2.4±0.17 fold activation of PPARα in comparison with the control condition (P<0.001). This relative activation is equivalent to 31.2% of the activity observed with the positive control, 100 µM of fenofibrate.
The observed PPARα relative activation of fenugreek extract may explain its reported hypolipidemic and hypocholesterolemic effects, and the increase of HDL. Fenugreek seeds and 4-OH-Ile decrease lipidemia [1] [2] [3] , which has been observed in type 1 and type 2 diabetes [6, 7] . For instance, it has been shown that a fenugreek seed extract standardized to contain 20% of 4-OH-Ile decreased the plasma triglyceride gain (P<0.05) and also reduced body weight (P<0.001) in obese mice fed with a high-fat diet during 20 days [3] . That fenugreek lowers cholesterol has been observed in dislipidemia [2] , hypercholesterolemia [4, 5] , and diabetes [6] . The hypocholesterolemic effect of fenugreek has also been confirmed using highly concentrated 4-OH-Ile fractions [2] . Fenugreek seeds and its 4-OH-Ile fraction also increase HDL cholesterol [1, 2, 7] . Fenugreek extract was also tested for its capacity to inhibit LDL oxidation. Figure 2 shows LDL oxidation curves and Table 1 reports the lag phase, oxidation rate, and maximum quantity of dienes produced by fenugreek extract and controls. Results show that fenugreek extract exerts inhibitory action against LDL oxidation induced by Cu 2+ in a dose dependent manner. Fenugreek extract (100 μg/mL) inhibits the oxidation of LDL increasing significantly the lag phase compared with the positive control (100 μM of Trolox ® ). Fenugreek extract also reduced the oxidation rate of LDL by 16.3% with 5 μg/mL (P<0.01) and by 63.7% with 25 μg/mL (P<0.001), showing complete inhibition with 100 μg/mL. It is noteworthy to say that at the highest concentration (100 μg/mL) fenugreek extract shows an activity similar to that of 100 μM Trolox ® . Based on our data, it seems that the high content of 4-OH-Ile and trigonelline in our fenugreek extract could be responsible for the inhibition of LDL oxidation induced by Cu 2+ . Until now, the reduction activity on LDL oxidation of fenugreek seed powder has been associated with its fiber content. It has been proposed that the fiber modifies the cholesterolemic profile in LDL causing a reduction in the amount of oxidized LDL in plasma [5] . This first report on a fenugreek seed extract to inhibit Cu 2+ -induced LDL oxidation brings new evidence and sustains the antioxidant capacity of fenugreek. Fenugreek seeds normalize disrupted free radical metabolism [11, 14] , decrease the peroxidative damage in plasma and organs [11] [12] [13] , and improve the antioxidant enzymatic status [12] [13] [14] .
In conclusion, our results suggest that fenugreek extract containing 4-OH-Ile and trigonelline induces activation of PPARα and exhibits inhibitory action against LDL oxidation induced by Cu 2+ in vitro. Our findings support current evidence for the capacity of fenugreek extract to control the Metabolic Syndrome. Therefore, the positive effects of fenugreek may help to create new products oriented to control obesity and diabetes, and to prevent cardiovascular disease. The molecular weights of the 4-OH-Ile isomer (2S,3R,4S) and trigonelline were identified by HPLC-MS and their chemical structures were determined by comparison of NMR data with those in literature [23, 24] . An HPLC method was developed for the quantification of the compounds in the fenugreek extract. The HPLC system used was an Agilent 1100 (Palo Alto, USA) equipped with an Evaporative Light Scattering Detector (ELSD, Sedere Sedex-75, France). ELSD operational conditions were set up at 2.3 bars, 40°C, and gain at 7. The stationary phase used was a Prevail Carbohydrate column (5 μm, 4.6 mm ID x 250 mm, Alltech, USA) thermostated at 30 o C. The mobile phases were (A) acetonitrile (Sigma, USA) and (B) water (Milli-Q, USA) running at 1 mL/min. A solution of 90% A and 10% B was maintained for 20 min and then changed to 70% A and 30% B, following a linear gradient to 20% A and 80% B after 25 min, maintaining this composition for 10 more min; the system was then reequilibrated to the initial composition after 10 min.
PPARα assay: The relative activations of PPARα by fenugreek extract and fenofibrate (positive control) as compared with DMSO (control condition) were calculated as the luminescence signal of luciferase (a gene reporter) obtained from the active compounds after incubation with GAL4/PPARα receptor transfected cells. First, COS-7 cells (cultured in DMEM + 10% FCS) were transiently transfected with a fusion protein GAL4/PPARα and a DNA construct carrying the luciferase. For the transfection, first the plasmid pGAL5-TK-pGL3 was obtained by inserting five copies of the GAL4 (yeast transcription factor) DNA binding site in front of the thymidine kinase promoter of the pTK-pGL3 plasmid. Then, the plasmid pGAL4-hPPARα was constructed by PCR amplifying the hPPARα DEF domains (aa180-464).
The resulting PCR products were cloned in pBD-GAL4 (Stratagene, La Jolla, USA) and the chimera subsequently subcloned into the pCDNA3 vector. After transfection, COS-7 cells were incubated for 24 h with 0 µg/mL (control condition), 1 µg/mL, 3 µg/mL, 10 µg/mL, 30 µg/mL, 100 µg/mL, and 1,000 µg/mL of fenugreek extract, or 100 µM of fenofibrate (positive control). DMSO was used as the solvent. After incubation, cells were collected and the luciferase assay was performed. The activation of PPARα by fenugreek extract and fenofibrate resulted in the expression of luciferase and consequent increment of the luminescent signals, which were measured with a Tecan Ultra Spectrophotometer (Tecan, Austria). Results were expressed as the relative activation of GAL4/PPARα proportional to the luminescent signal emitted as a result of the fenugreek extract and fenofibrate as compared to the luminescent activity of the control (DMSO). Results are reported as the mean ± SD of four trials for each test (Figure 1 ).
Cu
2+ -induced LDL oxidation assay: LDL was concentrated from the plasma of normolipidemic donors by density gradient ultracentrifugation. Prior to oxidation, LDL was diluted in a phosphate buffered saline (PBS) and dialyzed against PBS at 4°C to remove EDTA. The protein content was determined and adjusted to obtain 0.125 mg of protein/mL. Next, the oxidation was induced at 30°C by adding 100 mL of CuSO 4 (1.66 mM) with the addition of 0 μg/mL (control condition), 5 μg/mL, 25 μg/mL, and 100 μg/mL of fenugreek extract, or 10 μM and 100 μM of Trolox ® (positive control).
The amounts of conjugated dienes were measured by determining the increased absorbance at 234 nm at 10 min intervals for a course span of 720 min using a Tecan Ultra Spectrophotometer (Tecan, Austria). Results were expressed as the relative absorbance at 234 nm. The lag phase, oxidation rate, and the maximum quantity of conjugated dienes were calculated. Results are reported as the mean ± SD of three trials for each test (Figure 2 and Table 1 ). 
